Growth factors improve the in vivo migration of human skeletal myoblasts by modulating their endogenous proteolytic activity

Transplantation

Volumn 77, Issue 11, 2004, Pages 1741-1747

  Lafreniere, Jean Francois ^a   Mills, Philippe ^a   Tremblay, Jacques Pierre ^a   El Fahime, Elmostafa ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; GELATINASE; GELATINASE B; GROWTH FACTOR; MOTOGENIC FACTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL TRANSPLANTATION; CHEMOKINESIS; COCULTURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MYOBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING; ZYMOGRAPHY;

AMILORIDE; CELL MEMBRANE; CELL MOVEMENT; CELLS, CULTURED; FIBROBLAST GROWTH FACTOR 2; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SKELETAL; MYOBLASTS; PEPTIDE HYDROLASES; PHENYLALANINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE INHIBITORS; RECEPTORS, CELL SURFACE; SERINE PROTEINASE INHIBITORS; THIOPHENES; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 2942633256     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000131175.60047.EB     Document Type: Article

References (29)

1. Tremblay JP, Malouin F, Roy R, et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993; 2(2): 99.
2. Mendell JR, Kissel JT, Amato AA, et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995; 333(13): 832.
3. Skuk D, Vilquin JT, Tremblay JP. Experimental and therapeutic approaches to muscular dystrophies. Curr Opin Neurel 2002; 15(5): 563.
4. Kinoshita I, Huard J, Tremblay JP. Utilization of myoblasts from transgenic mice to evaluate the efficacy of myoblast transplantation. Muscle Nerve 1994; 17(9): 975.
5. Skuk D, Goulet M, Roy B, et al. Efficacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: toward defining strategies applicable to humans. Exp Neurol 2002; 175(1): 112.
6. Satoh A, Huard J, Labrecque C, et al. Use of fluorescent latex microspheres (FLMs) to follow the fate of transplanted myoblasts. J Histochem Cytochem 1993; 41(10): 1579.
7. El Fahime E, Mills P, Lafreniere JF, et al. The urokinase plasminogen activator: an interesting way to improve myoblast migration following their transplantation. Exp Cell Res 2002; 280(2): 169.
8. Allen DL, Teitelbaum DH, Kurachi K. Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol 2003; 284(4): C805.
9. Dunn SE, Torres JV, Nihei N, et al. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol Carcinog 2000; 27(1): 10.
10. Ikeo S, Yamauchi K, Shigematsu S, et al. Differential effects of growth hormone and insulin-like growth factor I on human endothelial cell migration. Am J Physiol Cell Physiol 2001; 280(5): C1255.
11. Suzuki J, Yamazaki Y, Li G, et al. Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts. Mol Cell Biol 2000; 20(13): 4658.
12. Rabinovsky ED, Gelir E, Gelir S, et al. Targeted expression of IGF-1 transgene to skeletal muscle accelerates muscle and motor neuron regeneration. FASEB J 2003; 17(1): 53.
13. Kinoshita I, Vilquin JT, Roy T, et al. Successive injections in mdx mice of myoblasts grown with bFGF. Neuromuscul Disord 1996; 6(3): 187.
14. Chakravarthy MV, Davis BS, Booth FW. IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. J Appl Physiol 2000; 89(4): 1365.
15. El Fahime E, Torrente Y, Caron NJ, et al. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp Cell Res 2000; 258(2): 279.
16. Nerlov C, Rorth P, Blasi F, et al. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6(9): 1583.
17. Morgan JE, Coulton GR, Partridge TA. Mdx muscle grafts retain the mdx phenotype in normal hosts. Muscle Nerve 1989; 12(5): 401.
18. Wells JM, Strickland S. Regulated localization confers multiple functions on the protease urokinase plasminogen activator. J Cell Physiol 1997; 171(2): 217.
19. Lewis MP, Tippett HL, Sinanan AC, et al. Gelatinase-B (matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase of human and murine muscle cell cultures. J Muscle Res Cell Motil 2000; 21(3): 223.
20. Hannocks MJ, Oliver L, Gabrilove JL, et al. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood 1992; 79(5): 1178.
21. Damiens C, Fortun Y, Charrier C, et al. Modulation by soluble factors of gelatinase activities released by osteoblastic cells. Cytokine 2000; 12(11): 1727.
22. Fibbi G, D'Alessio S, Pucci M, et al. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem 2002; 383(1): 127.
23. Miralles F, Ron D, Baiget M, et al. Differential regulation of urokinase-type plasminogen activator expression by basic fibroblast growth factor and serum in myogenesis. Requirement of a common mitogen-activated protein kinase pathway. J Biol Chem 1998; 273(4): 2052.
24. Bugge TH, Suh TT, Flick MJ, et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270(28): 16886.
25. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73(1): 161.
26. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214(1): 187.
27. Wang Y, Jones CJ, Dang J, et al. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 1994; 353(2): 138.
28. Degryse B, Sier CF, Resnati M, et al. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett 2001; 505(2): 249.
29. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16(10): 2610.